Satellos Bioscience (MSLE) Stock Analysis

What Satellos Bioscience does

Satellos Bioscience Inc., a biotechnology company, develops medicines to treat degenerative muscle diseases primarily in Canada and Australia. The company uses its proprietary platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo. It develops SAT-3247 an oral, small-molecule drug candidate for the treatment of Duchenne muscular dystrophy disease. The company has a license agreement the with Ottawa Hospital Research Institute (OHRI); and an option agreement with the University of British Columbia. Satellos Bioscience Inc. was founded in 2018 and is headquartered in Toronto, Canada.

Key metrics

ETFs linked to MSLE

Broad-market and Healthcare sector ETFs an investor holding Satellos Bioscience is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how MSLE fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Satellos Bioscience?

Satellos Bioscience trades under the ticker MSLE on NASDAQ.

Which exchange is MSLE listed on?

MSLE is listed on NASDAQ.

What sector does Satellos Bioscience operate in?

Satellos Bioscience is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze MSLE in a portfolio?

PortView shows MSLE's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.